According to results presented at the 42nd annual meeting of the American Society of Clinical Oncology (ASCO), treatment with chemotherapy and radiation therapy prior to surgery significantly improves survival compared to surgery alone in patients with operable esophageal cancer.
The esophagus is a tube that connects the back of the throat to the stomach. Early esophageal cancer refers to cancer that has not spread from its site of origin. Locally advanced esophageal cancer refers to cancer that has spread from its site of origin, but has not spread to distant sites in the body. Stages I-III esophageal cancer refer to early through locally advanced stages of the disease.
Standard treatment for locally advanced esophageal cancer includes surgery (if possible), chemotherapy, and radiation therapy. Neoadjuvant therapy (treatment prior to surgery), including chemotherapy and radiation therapy, is often used to reduce the size of the cancer prior to surgery; this allows for more complete surgical removal of the cancer. In addition, neoadjuvant therapy is thought to immediately kill cancer cells that may be in the body. Since results from previous trials evaluating survival with the use of neoadjuvant therapy have not been consistent, research continues to evaluate long-term survival with different treatment approaches.
Researchers associated with the Cancer and Leukemia Group B (CALGB) recently conducted a trial to directly compare different treatment approaches in esophageal cancer. This trial included 56 patients; 30 were treated with neoadjuvant chemotherapy and radiation therapy followed by surgery, and 26 were treated with surgery alone.
Mobocertinib Treatment for Non-Small Cell Lung Cancer with exon 20 Mutations
FDA grants breakthrough therapy status to Mobocertinib for treatment of patients with NSCLC and exon 20 mutations.
Tagrisso® - Standard of Care for EGFR + Non Small Cell Lung Cancer
FLAURA study confirms Tagrisso as best initial treatment of EGFR + NSCLC - learn more about its role in NSCLC management
Follow-up was approximately six years. Treatment with the addition of chemotherapy/radiation improved outcomes compared with surgery alone:
- Average survival was approximately 4.5 years for patients treated with chemotherapy/radiation/surgery, compared with only 1.8 years for those treated with surgery alone.
- Survival at five years was 39% for those treated with chemotherapy/radiation/surgery, compared with only 16% for those treated with surgery alone.
- 14 patients treated with chemotherapy and radiation suffered surgical complications, compared with 17 patients treated with surgery alone.
- Hospital stays following surgery were approximately 11.5 days in the group treated with chemotherapy/radiation, compared with 10 days for those treated with surgery only.
The researchers concluded that neoadjuvant therapy with chemotherapy and radiation therapy prior to surgery significantly improves survival compared with surgery alone in the treatment of stages I-III esophageal cancer. The presenter of these results stated that this treatment approach should be considered the new standard of care for treatment of this disease. However, it is important for patients to discuss their individual risks and benefits of all treatment approaches with their physician.
Reference: Tepper J, Krasna M, Niedzwiecki D, et al. Superiority of Trimodality Therapy to Surgery Alone In Esophageal Cancer: Results of CALGB 9781. Proceedings from the 42nd annual meeting of the American Society of Clinical Oncology (ASC). June 2006. Atlanta, GA. Abstract #4012.